Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adapt Pharma Ltd.

www.adaptpharma.com

Latest From Adapt Pharma Ltd.

Ohio Study Shows Access To Naloxone Soars Without Rx Requirement

JAMA study finds that removing Rx requirement for naloxone in Ohio resulted in a 2,328% increase in orders of the drug dispensed since 2015. Michael Hufford, CEO of a company working on an OTC switch for a naloxone nasal spray, says the results show urgent need for a low-cost OTC product.
OTC Drugs Drug Approval Standards

US FDA's Words Matter: Sharpless Says Injectable Naloxone OK For Community Distribution

The acting commissioner's statement is intended to clarify "persistent misunderstanding" about the label for the opioid overdose rescue medication's injectable formulation.

Neurology FDA

Purdue's Support For OTC Naloxone Would Continue In Bankruptcy

Bankrupt Purdue proposes continued funding for developing OTC naloxone product through firm to sell ‘millions of doses’ of the emergency opioid overdose product at low or no cost. Harm Reduction Therapeutics, which previously received funding from Purdue, has pushed back target date for NDA until early 2021 for its OTC naloxone nasal spray.
OTC Drugs Drug Approval Standards

Purdue's Opioid Rescue Drug Development To Continue Under A New Company

Purdue proposes continuing the development of nalmefene hydrochloride and other products under a new company that would provide the products at no or low cost.

Companies Research & Development
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Nasal
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Ireland
  • Parent & Subsidiaries
  • Adapt Pharma Ltd.
  • Senior Management
  • Seamus Mulligan, Chmn. & CEO
    David Brabazon, CFO
    Matt Ruth, Chief Commercial Officer
    Eunan Maguire, COO
    Fintan Keegan, CTO
    Ryan Loughlin, Dir., Drug Dev.
  • Contact Info
  • Adapt Pharma Ltd.
    Phone: 1 -6344-172
    45 Fitzwilliam Sq.
    Dublin 2,
    Ireland
UsernamePublicRestriction

Register